Strength Seen in Oculis Holding AG (OCS): Can Its 6.7% Jump Turn into More Strength?

Oculis Holding AG (OCS) shares soared 6.7% in the last trading session to close at $17.73. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.9% loss over the past four weeks.The sudden price rise can be attributed to growing investor optimism surrounding the company’s three product candidates, OCS-01, which is being developed in late-stage studies for treating diabetic macular edema, privosegtor (OCS-05), which is in mid-stage development for acute optic neuritis and licaminlimab (OCS-02), which is being developed with a genotype-based approach to drive personalized medicine in dry eye disease.This company is expected to post quarterly loss of $0.50 per share in its upcoming report, which represents a year-over-year change of +9.1%. Revenues are expected to be $0.25 million, down 1.6% from the year-ago quarter.Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.For Oculis Holding AG, the consensus EPS estimate for the quarter has been revised 7.3% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on OCS going forward to see if this recent jump can turn into more strength down the road. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Oculis Holding AG belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Incyte (INCY), closed the last trading session 2.1% lower at $84.73. Over the past month, INCY has returned 1.8%.Incyte's consensus EPS estimate for the upcoming report has changed +0.4% over the past month to $1.64. Compared to the company's year-ago EPS, this represents a change of +53.3%. Incyte currently boasts a Zacks Rank of #3 (Hold).Zacks Names #1 Semiconductor StockThis under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Oculis Holding AG (OCS): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks